Early activity and tolerability were observed among patients who received setidegrasib, an investigational KRAS G12D-targeted protein degrader, for non–small cell lung cancer (NSCLC) harboring KRAS G12D mutations, according to data from a phase 1 trial presented at the 2026 European...
Setidegrasib showed promising activity in KRAS G12D-mutant NSCLC and pancreatic cancer, supporting protein degradation as a new precision oncology strategy Setidegrasib in KRAS G12D-Mutant NSCLC and Pancreatic Cancer: A New Frontier Opens in Precision Oncology For years, KRAS G12D has...
For oncology nurses caring for patients with KRAS G12C-mutant metastatic non–small cell lung cancer (NSCLC), new data from the phase 1 KANDLELIT-001 trial (NCT05067283) suggest a shifting treatment landscape. Findings presented at the 2026 European Lung Cancer Congress (ELCC) demonstrate...
Data from a phase 1 study (NCT05382559) presented at the 2026 European Lung Cancer Congress (ELCC) and published in The New England Journal of Medicine indicate that setidegrasib, a first-in-class protein degrader, yielded significant antitumor activity with a tolerable safety...
Calderasib (MK-1084) alone or in combination with pembrolizumab (Keytruda) demonstrated clinically meaningful and durable antitumor activity across multiple treatment settings in patients with KRAS G12C–mutated metastatic non–small cell lung cancer (NSCLC), with particularly high response rates and prolonged progression-free survival...
Treatment with adagrasib (Krazati) resulted in meaningful clinical benefit and manageable toxicities in elderly patients with pretreated non–small cell lung cancer (NSCLC) who displayed a KRAS G12C mutation and had an ECOG performance status (PS) of 0 or 1 (cohort...
ADEPPT trial results at ELCC showed adagrasib activity in elderly patients with pretreated KRAS G12C-mutant NSCLC ADEPPT Trial at ELCC: Adagrasib in Underrepresented KRAS G12C-Mutant NSCLC Populations ADEPPT Trial , presented by Jarushka Naidoo (Dublin, Ireland) at ELCC, explored the...
ADEPPT Trial at ELCC: Adagrasib in Underrepresented KRAS G12C-Mutant NSCLC Populations ADEPPT Trial , presented by Jarushka Naidoo (Dublin, Ireland) at ELCC, explored the efficacy, safety, and quality-of-life outcomes of adagrasib in underrepresented populations with pretreated KRAS G12C-mutant non-small cell...
Setidegrasib displayed efficacy with a tolerable safety profile for the treatment of patients with KRAS G12D-mutant non–small cell lung cancer (NSCLC), according to data from a phase 1 study (NCT05382559) presented during the 2026 European Lung Cancer Congress and simultaneously...
